News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1293
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 79de34c95adeea80b3cf.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-25 08:43:38
            [updated_time] => 2025-04-15 14:58:16
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => PGT-M-for-100+-rare-diseases-a-solution-for-healthy-babies-in-families-carrying-genetic-disorders
            [title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential. In an effort to eliminate the fear of rare diseases from the community, GENTIS has researched and developed a PGT-M test capable of screening for over 100 rare diseases.
            [content] => 
Rare Diseases – A Group That Demands Attention
Rare diseases are conditions that occur infrequently in the general population, usually caused by genetic mutations, and often have a severe impact on a patient’s health. According to the World Health Organization (WHO), a disease is considered rare when it affects fewer than 1 in 2,000 people. While each disease is rare individually, over 7,000 rare diseases have been identified, affecting approximately 300 million people worldwide.
These diseases are typically serious due to their complex nature and the lack of effective treatments. Many manifest severely from birth, leading to congenital defects, developmental delays, high mortality rates, or lifelong disabilities. Because of the low prevalence, developing treatments and diagnostics remains a major challenge, limiting access to care.
However, advancements in genetics, assisted reproduction, and prenatal diagnostics have expanded our ability to screen and manage rare diseases, offering hope for couples wanting to conceive and give birth to healthy children.
PGT-M for 100+ Rare Diseases: Bringing Hope to Families with Genetic Risks
In clinical practice and research, medical genetics plays an increasingly vital role. Preimplantation Genetic Testing for Monogenic Disorders (PGT-M), combined with assisted reproductive technologies, has brought joy to many infertile couples by allowing them to have healthy children and contribute to reducing the incidence of monogenic rare diseases in the community.
PGT-M is performed during in vitro fertilization (IVF) and is used to detect and select embryos free from disease-causing genetic mutations before embryo transfer into the uterus
GENTIS Utilizes Modern Technologies for PGT-M Testing
PGT-M plays a key role in screening and preventing rare diseases, especially in couples with a family history of genetic conditions. By ensuring that only embryos without the disease-causing gene are transferred, this test not only reduces the burden of genetic disease on families but also improves the overall health of future generations.
Applying PGT-M in assisted reproduction marks a significant breakthrough in medicine, offering hope and a path forward for couples who wish to have healthy children, while reducing the risk of passing on rare genetic diseases.
At GENTIS, PGT-M can detect over 100 rare diseases caused by gene mutations, helping minimize the risk of giving birth to a child with a severe genetic disorder.
A Highly Skilled Team at GENTIS
Outstanding Advantages of the PGT-M Test for 100+ Rare Diseases:
This specialized test not only brings hope to couples carrying genetic disorders but also offers multiple advantages for optimizing genetic screening right from the embryonic stage.
One of the most significant benefits of GENTIS’s PGT-M test is the ability to accurately analyze over 100 monogenic disorders, capable of detecting even subtle variations in DNA that may cause disease.
Using next-generation sequencing (NGS) technology combined with customized family-specific marker design, PGT-M ensures precise identification of healthy embryos, increasing the chances of a successful, healthy pregnancy.
Additionally, the PGT-M service for 100+ rare diseases is supported by a team of expert genetic counselors, who guide patients before, during, and after the testing process.
Expert-Led, Patient-Centered Genetic Counseling at GENTIS
Before testing, counselors help couples understand their genetic risks, explain disease mechanisms, and assess the necessity of the test. Throughout the testing process, experts closely monitor each stage to ensure result accuracy and appropriateness.
After results are available, the team continues to provide support by interpreting clinical implications, guiding couples in selecting the best embryos, and proposing tailored reproductive strategies if necessary.
Thus, PGT-M is more than a screening tool — it is a comprehensive solution, offering peace of mind to families at risk of transmitting genetic conditions.
According to Assoc. Prof. Dr. Francesca Spinella (Former Chair of the ESHRE PGT Consortium and Genetic Consultant at Eurofins GENTIS), PGT-M plays a vital role in the field of reproductive medicine. This test allows for the screening of monogenic disorders and ensures that only embryos without genetic mutations are transferred — bringing hope to couples struggling with infertility and genetic risks.
            [content_more] => 
            [meta_title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [meta_description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential
            [meta_keyword] => GENTIS,pgt-m
            [thumbnail_alt] => 
            [post_id] => 1293
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1292
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02511.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-24 16:00:41
            [updated_time] => 2025-04-15 14:52:29
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => GENTIS-accompanies-the-2025-clinical-embryology-conference
            [title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM), will be held on March 22–23, 2025. The conference aims to provide opportunities for professional updates, knowledge exchange, and the presentation of scientific research in the field of clinical embryology. GENTIS is honored to be a sponsor of this important event.
            [content] => 
At the conference, leading experts in IVF will present and discuss various issues related to clinical embryology and IVF laboratories. Some of the key topics covered include:


Quality management and new techniques



Embryo genetic testing


Sperm-related factors


Poor prognosis cases


Embryo culture and cryopreservation


Embryos from abnormal fertilization and abnormal oocytes



Notably, GENTIS is proud to have provided PGT-M testing data for the presentation by Resident Doctor Lê Thảo Ly (Quang Ninh Obstetrics and Pediatrics Hospital), titled: "Evaluating the Live Birth Rate Following Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) for Thalassemia at Quang Ninh Obstetrics and Pediatrics Hospital from 2022–2024."
According to Dr. Thảo Ly, Thalassemia is the most common autosomal recessive inherited anemia worldwide, including in Vietnam. This disease significantly impacts the physical and mental well-being of patients and their families. While there is currently no definitive cure, it can be proactively prevented and screened. Importantly, the introduction of PGT-M has helped reduce the risk of giving birth to children affected by Thalassemia.
At GENTIS, the PGT-M test is conducted using cutting-edge technologies and modern equipment, including Veriseq PGS, next-generation sequencing (NGS) with Illumina technology (USA), and SNP/STR analysis methods. This ensures the high reliability of test results. Currently, GENTIS is capable of screening for more than 100 monogenic diseases using PGT-M.

As a sponsor of the conference, GENTIS presented an impressive booth with a variety of engaging activities, drawing great interest from many delegates. Highlights included:


Introducing advanced, modern solutions for preimplantation embryo genetic screening tailored to improve healthcare outcomes for the Vietnamese population, particularly two new PGT testing packages: PGT NEXT and PGT UPGRADE



Providing the latest genetic testing materials in the field of assisted reproduction


Offering attractive appreciation gifts to participating delegates



Over the years, GENTIS has regularly participated in conferences and seminars to stay updated with the latest insights, technologies, and advancements in IVF. Our goal is to provide effective and accurate genetic testing for patients.
The 2025 Clinical Embryology Conference concluded successfully, offering a wealth of knowledge, clinical expertise, and updates on trends, technologies, and treatment protocols. It also signals promising growth in Vietnam’s reproductive health sector in the years ahead.
            [content_more] => 
            [meta_title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [meta_description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM
            [meta_keyword] => gentis,CEC
            [thumbnail_alt] => 
            [post_id] => 1292
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1291
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => fd00c58f1d82addcf493.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-24 15:16:39
            [updated_time] => 2025-04-15 14:49:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Recommendation-on-mutation-confirmation-prior-to-performing-preforming-preimplantation-genetic-testing-for-monogenic-diseases-PGT-M
            [title] => 
            [description] => GENTIS is a pioneer in the field of genetic analysis, providing the best and most advanced services and tests to customers and partners with the goal of enhancing the physical and intellectual well-being of the Vietnamese people — including PGT-M testing.

            [content] => 
PGT-M (Preimplantation Genetic Testing for Monogenic diseases) is a genetic screening test performed on embryos to identify and select embryos that do not carry disease-causing genetic mutations inherited from the parents. This test is typically recommended for couples who are carriers of mutations linked to genetic disorders and wish to prevent passing these conditions on to their children. As it is performed before embryo transfer, this early screening method helps avoid the risk of children being born with genetic diseases and reduces the need for pregnancy termination due to severe genetic abnormalities.
To ensure accuracy and compatibility with GENTIS' testing protocols, and to protect customer rights during the PGT-M testing process, we issue the following recommendations regarding the submission of genetic test results before performing PGT-M:


In cases where genetic test results are provided from a family member affected by the condition (e.g., children, siblings, etc.), mutation confirmation in the couple intending to undergo PGT-M is MANDATORY.


In cases where genetic test results are provided from the couple intending to undergo PGT-M:


If the test was performed at GENTIS: The result is accepted for use in PGT-M, and GENTIS takes full responsibility for the accuracy of this result.


If the test was performed at another laboratory: Sanger sequencing data must be provided, or it is recommended that mutation confirmation be redone at GENTIS.




Why does GENTIS require mutation confirmation in parents before performing PGT-M?


Commitment to quality and medical responsibility: GENTIS is fully accountable for the results of tests it performs. We cannot guarantee the accuracy of tests conducted by third parties.


The genetic test results directly impact the PGT-M process and its outcomes.


Ensuring customer rights during PGT-M testing: Confirming the mutation in the couple allows doctors to make appropriate decisions regarding PGT-M, preventing scenarios where patients undergo an IVF cycle but cannot proceed with PGT-M due to inadequate testing.




Important Recommendation 
If you are considering PGT-M testing, we strongly recommend that it be performed directly at GENTIS to ensure the highest level of accuracy, consistency, and compatibility with your treatment plan.
Contact GENTIS' expert team to have all your questions answered before proceeding with testing.
 GENTIS is committed to providing accurate, safe, and optimized testing services — ensuring a complete and satisfying experience for our clients.
GENTIS HOTLINE: 1800 2010
 Website: gentis.com.vn


            [content_more] => 
            [meta_title] => Recommendation on Mutation Confirmation Prior to Performing Preimplantation Genetic Testing for Mono
            [meta_description] => GENTIS is a pioneer in the field of genetic analysis, providing the best and most advanced services and tests to customers and partners with the goal of enhancing the physical and intellectual well-being of the Vietnamese people — including PGT-M testing.
            [meta_keyword] => GENTIS,PGT-M
            [thumbnail_alt] => Recommendation on Mutation Confirmation Prior to Performing Preimplantation Genetic Testing for Monogenic Diseases (PGT-M)
            [post_id] => 1291
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1290
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b7db2d93bf200e7e5731.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 15:58:16
            [updated_time] => 2025-03-18 16:03:00
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-pgt-next-va-pgt-upgrade-tai-benh-vien-buu-dien-d1290
            [title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing two newly launched PGT testing packages: PGT NEXT and PGT UPGRADE. Throughout the seminar, GENTIS representatives discussed and answered questions from doctors at the Post Office Hospital about these new genetic testing packages.
            [content] => 
Attending the seminar, on behalf of the IVF Center, the Post Office Hospital had the presence of Master. Doctor Bach Huy Anh (Deputy Director), Master. Doctor Chu Thi Huong, Doctor CKI. Kieu Duc Ty and doctors of the department. Representing GENTIS, there was the participation of Mr. Nguyen Quang Vinh (Director of Testing Center) and Mr. Nguyen Van Huynh (Leader of R&D).
Mr. Vinh and Mr. Huynh gave a detailed introduction to the two test packages PGT NEXT and PGT UPGRADE of GENTIS. Sharing with the doctors of the HTSS Center - Post Office Hospital, Mr. Huynh emphasized the technological breakthrough of both new PGT tests.

Accordingly, the PGT NEXT test is a test that can detect haploid/polyploid embryos. According to statistics during the research process at GENTIS: "Haploid/polyploid abnormalities occur in 1-3% of all pregnancies and triploidy accounts for 15-18% of miscarriages." Therefore, detecting haploid/polyploid embryos is highly significant in increasing the success rate of IVF.
In addition, PGT NEXT also supports and complements PGT-A/SR, helping to detect polyploid embryos and identify embryos with normal diploid chromosome sets, even in abnormally fertilized embryos (e.g., 0PN, 1PN, or 2.1/3PN).
This test can be extended to patients with a history of polyploidy, molar pregnancy, and miscarriage after IVF combined with traditional PGT-A, increasing the number of embryos that can be transferred from abnormally fertilized zygotes (0PN, 1PN, or 2.1/3PN). The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect polyploidy.

For PGT UPGRADE, this is a test to detect embryos carrying balanced translocations. "Balanced translocation is the phenomenon of exchanging DNA segments between non-homologous chromosomes without increasing or decreasing genetic material at the breakpoints. In balanced translocation, there are also two types: Reciprocal translocation and Robertsonian translocation."
The PGT UPGRADE test is indicated for couples with a history of recurrent miscarriage, a family history of chromosomal abnormalities, or spouses carrying balanced translocations who do not want to pass them on to the next generation. The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect embryos carrying balanced translocations.
The outstanding advantage of the PGT NEXT and PGT UPGRADE tests is the use of specialized bioinformatics software optimized specifically for the Vietnamese population. Therefore, these two tests not only help detect genetic abnormalities but also help reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to be placed in the uterus.

At the end of the presentation, doctors at the Post Office Hospital asked many questions about PGT NEXT and PGT UPGRADE, specifically: "Is 18% of the total number of embryos the proportion of euploid embryos carrying balanced translocations?", "With this new technology, is the cost of performing PGT UPGRADE much higher than the cost of performing PGT-A?". Thanks to the detailed answers of the GENTIS representative, the doctors had a clearer view and could visualize the future development of the PGT NEXT and PGT UPGRADE tests.

The seminar took place in a very exciting atmosphere and received a lot of attention and positive feedback from the participating doctors. Master, Doctor Bach Huy Anh shared: "Thank you GENTIS for coming to our hospital today and updating new products that are extremely meaningful and highly practical. For me personally, the PGT UPGRADE test has a high humanitarian significance, helping couples with balanced translocation genes prevent the possibility of passing it on to future generations. I believe that in the future, these two tests will greatly support infertile couples with multiple miscarriages, helping them reach their dream of becoming parents."
            [content_more] => 
            [meta_title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [meta_description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1290
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1289
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f6d5e56ee8de598000cf.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 14:29:48
            [updated_time] => 2025-03-18 14:36:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-tai-tro-hoi-nghi-phoi-hoc-lam-sang-nam-2025-cec-lan-thu-6-d1289
            [title] => GENTIS sponsors Clinical Embryology Conference 2025 - CEC 6
            [description] => Time: 22 - 23/03/2025
Location: Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh
            [content] => 
On March 22-23, 2025, Clinical Embryology Conference 2025 - organized by the Ho Chi Minh City Association of Reproductive Endocrinology and Infertility (HOSREM) will be held at Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh. GENTIS Genetic Testing Service Joint Stock Company is honored to be a sponsor of the conference.
The 6th CEC is a specialized conference on clinical embryology and new technical and technological applications in assisted reproduction. This year's conference will update knowledge, technical trends, technology, and new protocols in assisted reproductive techniques.
At the exhibition booth at the conference, GENTIS will focus on introducing solutions in genetic screening and diagnosis in the field of assisted reproduction, especially 2 new PGT test packages: PGT NEXT and PGT UPGRADE

PGT UPGRADE
PGT UPGRADE is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions with a size of over 5 Mb, especially capable of detecting embryos carrying balanced translocations inherited from the parents. Chromosomal translocations are structural abnormalities of chromosomes caused by the rearrangement of large segments between non-homologous chromosomes. There are two types of translocations: balanced (no loss of genetic material) and unbalanced (loss or extra genetic material, such as aneuploidy). When both the father and mother carry balanced translocations, approximately 60% of gametes will carry unbalanced translocations, leading to embryos with chromosomal abnormalities. This is also a common cause of repeated implantation failure, recurrent miscarriage, and birth defects. PGT UPGRADE test helps to select euploid embryos for parents carrying balanced translocations to increase the chance of having a healthy baby. In addition, PGT UPGRADE also supports providing genetic information for the embryo selection process before embryo transfer.
Performing PGTest testing can select genetically good quality embryos to increase the chance of pregnancy when performing in vitro fertilization (IVF), helping to increase the chance of the child being born healthy, without the screened genetic abnormalities.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosome structural abnormalities (addition, deletion) with a size of over 5 Mb.
- Detecting embryos carrying balanced genetic translocations from parents.
Method: Next-generation sequencing NGS (Illumina) and analyzing sequencing results using specialized bioinformatics software.
Samples used:
- Parental samples (2-3 ml whole blood in EDTA anticoagulant tube) and balanced translocation test results.
- Embryo biopsy sample on day 5.
Time to return results: 12 – 14 days.
PGT NEXT
PGT NEXT is a pre-implantation genetic analysis test that can detect aneuploidy on 24 chromosomes, chromosomal abnormalities, and chromosomal deletions. It can also detect embryos with polyploidy or haploidy. This helps avoid transferring polyploid/haploidy abnormal embryos, and avoid wasting euploid embryos with fertilization abnormalities (0PN, 1PN, and 2.1/3PN). In addition, the PGT UPGRADE test also supports the provision of genetic information for embryo selection before embryo transfer. The combination of NGS whole genome sequencing with SNP analysis improves the resolution of genetic screening for polyploidy.This method allows for the identification of haploid and polyploid chromosome sets, increasing the number of healthy euploid embryos available for transfer by accurately detecting true diploid embryos among abnormally fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Additionally, SNP analysis ensures precise identification of whether the tested embryo is genetically related to other embryos in the same cohort, thereby reducing the risk of sample mix-ups due to procedural or handling errors.
Detection range:
- Aneuploidy of all 24 chromosomes.
- Chromosomal structural abnormalities (addition, deletion).
- Detection of embryos with polyploidy or haploidy.
Method: Whole genome sequencing and sequencing of target markers on the next generation sequencing machine NGS.
Samples used: Embryo biopsy sample on day 5.
Time to return results: 3 – 4 weeks.
Not only that, GENTIS's booth also provides the latest genetic testing documents in the field of assisted reproduction and prepares many attractive gifts of gratitude to the delegates
️We respectfully invite doctors/ embryologists/ experts to visit GENTIS's booth to update the most modern and advanced pre-implantation genetic screening testing solutions, serving the needs of better medical examination and treatment of Vietnamese people.
            [content_more] => 
            [meta_title] => GENTIS sponsors Clinical Embryology Conference 2025 - CEC 6
            [meta_description] => On March 22-23, 2025, Clinical Embryology Conference 2025 - organized by the Ho Chi Minh City Association of Reproductive Endocrinology and Infertility (HOSREM) will be held at Wyndham Legend Halong Hotel, No. 12 Bai Chay, Ha Long City, Quang Ninh.
            [meta_keyword] => gentis,Cec
            [thumbnail_alt] => 
            [post_id] => 1289
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1287
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 90de80bcd93e6860312f.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-14
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-15 08:33:23
            [updated_time] => 2025-03-17 16:01:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-fish-va-2-goi-xet-nghiem-pgt-moi-tai-bv-san-nhi-phu-tho-d1287
            [title] => GENTIS introduces FISH test and 2 new PGT test packages at Phu Tho Obstetrics and Pediatrics Hospital
            [description] => On the afternoon of March 12, GENTIS coordinated with Phu Tho Obstetrics and Pediatrics Hospital to organize a seminar introducing the FISH test and two newly launched PGT test packages: PGT NEXT and PGT UPGRADE. At the seminar, GENTIS representatives discussed and answered questions from doctors at Phu Tho Obstetrics and Pediatrics Hospital about these new genetic test packages.
            [content] => 
Attending the seminar, on behalf of the Center for Reproductive Support, Phu Tho Obstetrics and Pediatrics Hospital, there was the presence of Dr. Doan Trung Kien (Director), Dr. Nguyen Thi Mai (Deputy Director), Dr. Le Ngoc Tue Nhi (Head of IVF Lab) and doctors of the department. Representing GENTIS, there were Mr. Nguyen Van Huynh (Head of R&D Group) and Dr. Vu Thu Huong.
At the seminar, Dr. Vu Thu Huong gave a detailed presentation on FISH, the process, principles and values ​​that this test brings. In addition, Mr. Nguyen Van Huynh also introduced and presented in detail about the two PGT NEXT and PGT UPGRADE test packages of GENTIS. One of the highlights of the seminar was the discussion about the benefits and technology applied to the two newly launched PGT products of GENTIS. According to Mr. Nguyen Van Huynh, thanks to the use of specialized bioinformatics software optimized for the Vietnamese population, this test not only helps detect genetic abnormalities but also helps reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to place in the uterus.
PGT testing helps couples avoid difficult situations, such as facing an unhealthy pregnancy or the risk of giving birth to a child with a serious genetic disease. Especially for older couples or couples with a history of genetic disease, PGT is an effective solution, helping to screen and select healthy embryos, thereby increasing the chance of having a safe and healthy child.
During the seminar, doctors at Phu Tho Obstetrics and Pediatrics Hospital asked many questions about FISH testing as well as PGT NEXT and PGT UPGRADE: "Can embryonic cells after FISH be used for other tests?", "The time to return results of PGT NEXT seems a bit long, can it be reduced in the future?". Accordingly, Mr. Nguyen Van Huynh and Dr. Vu Thu Huong gave extremely detailed answers, delving into the issues that doctors were still wondering about. This provided doctors with a clearer understanding of the future development of FISH, PGT NEXT and PGT UPGRADE tests at GENTIS.
The seminar took place in an engaging and dynamic atmosphere and received a lot of attention and positive feedback from the participating doctors. Dr. Doan Xuan Kien said: "I am very grateful and appreciate the presence of GENTIS today, thank you for organizing such a meaningful and practical seminar, helping doctors to update new knowledge about FISH testing, as well as better understand the breakthrough and necessity of applying PGT NEXT, PGT UPGRADE in pre-embryo genetic testing technology. These tests are not only a great step forward in medicine but also bring a new ray of hope to couples on the journey to find their beloved children".
Hopefully after the seminar, GENTIS and Phu Tho Maternity and Pediatrics Hospital will have more opportunities to cooperate for the development of both units!
            [content_more] => 
            [meta_title] => GENTIS introduces FISH test and 2 new PGT test packages at Phu Tho Obstetrics and Pediatrics Hospita
            [meta_description] => GENTIS coordinated with Phu Tho Obstetrics and Pediatrics Hospital to organize a seminar introducing the FISH test and PGT NEXT, PGT UPGRADE. 
            [meta_keyword] => gentis,Pgt,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1287
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1286
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02895.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-14
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-14 09:09:13
            [updated_time] => 2025-03-14 15:58:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-tiep-don-doan-chuyen-gia-illumina-den-tham-quan-va-lam-viec-d1286
            [title] => GENTIS welcomes Illumina experts to visit and work
            [description] => On March 13, GENTIS was honored to welcome Illumina experts to visit and work in Hanoi. The delegation was led by Ms. Katie Battese Ellis - Senior Director, Medical Affairs of Illumina in charge of several countries in the APAC region, along with Illumina experts in Vietnam.
            [content] => 

GENTIS representatives welcomed the delegation with Mr. Do Manh Ha - General Director, Dr. Pham Dinh Minh - Director of R&D and related departments/offices. At the meeting, the delegation visited the office area, the international standard GENTIS Eurofins Laboratory and shared experiences and genetic knowledge with GENTIS. Accordingly, Ms. Katie highly appreciated the design, equipment, and machinery of GENTIS's lab and hoped to have more opportunities to accompany the company.

GENTIS believes that Illumina - the world's leading Biotechnology group in human health and genomics, a pioneer in innovating the future of precision health, will be a reliable and long-term partner, helping GENTIS develop rapidly and sustainably in the future! As a partner of Illumina in Vietnam, GENTIS will continue to conquer new applications and technologies to bring more value to customers and patients, with the ambition to pioneer becoming a unit with a comprehensive genetic ecosystem.

With 15 years of experience in building and operating a modern Genetic Testing Center, GENTIS is ready to welcome domestic and foreign medical units to visit, share, exchange experiences, and learn to improve the quality of testing to serve doctors in accurate diagnosis, effective treatment for patients, as well as better health care for people every day. GENTIS Hanoi is proud to own a modern LAB, surpassing many strict domestic and international quality standards: ​

Area up to 2,000m2
Located in the city center, convenient transportation
GENTIS Eurofins laboratory system meets ISO 9001:2015, ISO 15189:2022, ISO 13485:2016, ISO/IEC 27001:2022 standards and aims for CAP standards
Leading technology equipment from the US, Europe, Korea... such as: New generation sequencing NGS; iScan system; Realtime PCR technique; Sanger sequencing; Flow Cytometry Technique
Process of testing in a professional lab, ensuring accuracy
Highly specialized R&D team
Technical team for sample collection and testing are well-trained and specialized

            [content_more] => 
            [meta_title] => GENTIS welcomes Illumina experts to visit and work
            [meta_description] => On March 13, GENTIS was honored to welcome Illumina experts to visit and work in Hanoi. The delegation was led by Ms. Katie Battese Ellis
            [meta_keyword] => gentis,Illumina
            [thumbnail_alt] => 
            [post_id] => 1286
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1284
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 696d27fcb92a0874513b.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-11
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-11 15:58:39
            [updated_time] => 2025-03-15 10:52:37
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/tien-si-pham-dinh-minh-bao-cao-tai-hoi-nghi-y-sinh-hoc-tzu-chi-academia-sinica-lan-thu-7-d1284
            [title] => Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference
            [description] => On March 8, 2025, Dr. Pham Dinh Minh (Director of R&D GENTIS - Director of GENTIS Genetic Counseling Center) gave a report at the 7th Tzu Chi - Academia Sinica Biomedical Conference at Tzu Chi University, Hualien, Taiwan. The report was on the topic: "Development and application of AI/Bioinformatics in genetic and genomic testing in Vietnam".
            [content] => 
The 7th Tzu Chi - Academia Sinica Biomedical Conference
The 7th Tzu Chi - Academia Sinica Biomedical Conference 2025 was held at Tzu Chi University, Hualien City, Taiwan. This year's conference focused on the theme of “Applications of AI in Biomedical Research” and “Multidisciplinary Perspectives in Biomedical Research & Therapy”.
Dr. Pham Dinh Minh - Director of R&D GENTIS (standing in the middle) with experts at Tzu Chi University
The conference brings together leading scientists and experts in the field of biomedical science in the world from the US, Japan, Korea, Vietnam, Thailand, Indonesia, Philippines, etc. The conference provides delegates as well as the community developing artificial intelligence in medicine in general, biomedicine in particular, with the latest research and development as well as the market in the field of research and application of AI.
Report by Dr. Pham Dinh Minh at the 7th Tzu Chi - Academia Sinica Biomedical Conference
The application of genetic and genomic testing is booming in the healthcare sector in Vietnam. Recently, we have witnessed the rapid application of tests in many healthcare areas, such as reproductive health, obstetrics and gynecology, newborn screening, cancer and cardiovascular diseases…
As we know, the development of AI has attracted many people, especially those working in the field of research and development. For the general community, the development of AI tools such as China's Deepseek or xAI's Grok has greatly changed the development as well as the application in social life.

Dr. Minh presented the report "Development and application of AI/Bioinformatics in genetic and genomic testing in Vietnam"
In the medical field, although still very new, AI has also been developed. In Vietnam, there are very good potentials, especially the amount of data, the huge amount of data related to health and testing. In particular, GENTIS is one of the large testing units and has a huge amount of data in Vietnam about genetic testing, gene testing. This is one of the advantages of GENTIS to be able to apply to develop as well as research AI in the testing field.
At the 7th Tzu Chi - Academia Sinica Biomedical Conference, the report on the topic "Development and application of AI/Bioinformatics in genetic and gene testing in Vietnam" by Dr. Pham Dinh Minh (Director of R&D GENTIS - Director of GENTIS Genetic Counseling Center) attracted the attention of many attending experts. In the report, Dr. Pham Dinh Minh shared research and applications of AI and bioinformatics in genetic and gene testing, aiming to develop new tests and improve the quality of testing. Especially genetic testing in pre-implantation embryo screening, genetic testing in non-invasive prenatal screening as well as other genetic and gene testing.

Dr. Minh received a certificate at the 7th Tzu Chi - Academia Sinica Biomedical Conference
In addition, the report also provides the conference, as well as the Asia-Pacific scientific community, with information on the development, research, and application of AI, as well as bioinformatics in Vietnam in general and the medical, genetic and genetic testing fields in Vietnam in particular.
GENTIS applies AI/bioinformatics software in genetic research and testing
“Developing AI applications/bioinformatics software is one of the key, main areas that GENTIS is oriented to develop in the coming time. GENTIS is looking forward to finding opportunities to cooperate with partners as well as developing further, researching and developing the latest directions of artificial intelligence applications as well as applying AI technology in genetic testing, genetic testing to bring new and improved tests, improving the quality of current tests”, Dr. Pham Dinh Minh shared more.
Currently, GENTIS has research projects and applications of artificial intelligence as well as bioinformatics in the field of genetic and genetic testing. Specifically, GENTIS is researching and developing AI tools, bioinformatics tools for embryo screening, improving the quality of pre-implantation genetic testing for embryos, and non-invasive prenatal screening NIPT.
Technological autonomy will help improve testing efficiency, optimize testing, improve testing quality, and use Vietnamese data. At the same time, it can help reduce testing costs, as well as bring different testing packages and testing features into GENTIS's current testing packages and testing services.
            [content_more] => 
            [meta_title] => Dr. Pham Dinh Minh reported at the 7th Tzu Chi - Academia Sinica Biomedical Conference
            [meta_description] => On March 8, 2025, Dr. Pham Dinh Minh gave a report at the 7th Tzu Chi - Academia Sinica Biomedical Conference at Tzu Chi University, Hualien, Taiwan.
            [meta_keyword] => gentis,Ai
            [thumbnail_alt] => 
            [post_id] => 1284
            [category_id] => 4
        )

)